Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research found that exosome-derived long non-coding RNA AC010789.1, modified by FTO and hnRNPA2B1, enhanced human hair follicle stem cell proliferation against androgenic alopecia through the activation of S100A8/Wnt/β-catenin signaling pathways.

This study found that overexpression of the lncRNA AC010789.1 in hair follicle stem cells may suppress androgen alopecia progression by modulating several molecular pathways, suggesting a potential new treatment strategy.

This study found that targeting the AR/miR-128-3p/IGF-1 pathway with ASLNC168501 shows potential for treating androgenetic alopecia by restoring hair follicle stem cell function and promoting hair regeneration.

This study identified seven genes that may serve as biomarkers for diagnosing skin cutaneous melanoma by analyzing the relationship between UV exposure, ferroptosis, and the cancer's pathology.

This study analyzed gene expression data to identify key genes involved in severe forms of alopecia areata, discovering four immune monitoring genes (LGR5, SHISA2, HOXC13, S100A3) with potential for early diagnosis and better understanding of the disease's biological mechanisms.

This study found that men aged 18-40 with moderate to severe psychosocial impairment from male androgenetic alopecia had a higher risk of sexual dysfunction.

This study observed that PCAT1 and HOTAIR gene expressions were significantly lower in individuals with androgenic alopecia compared to healthy controls, suggesting their potential involvement in the condition's pathogenesis.

This study identified four hub genes that are closely linked to the causative factors of androgenetic alopecia, suggesting potential diagnostic and therapeutic targets.

This study found that the prevalence of androgenetic alopecia in Turkish society is higher than in Asian and African communities but similar to European populations.

This review covers the structure, development, cycle, and molecular regulation of hair follicles but does not report new results, aiming to offer insights for addressing hair follicle-related diseases.

Targeting S100 proteins may help treat hair loss.

This study found that bovine milk-derived exosomes (MEV-miRNAs) significantly increased hair follicle dermal papilla cell viability and up-regulated key WNT signaling components in human hair follicles, suggesting potential therapeutic benefits for androgenetic alopecia and telogen effluvium through modulation of hair growth pathways.

This study found that while exosome therapy shows promise for treating AGA, AA, and CIA, its integration into routine practice will depend on rigorous clinical trials and standardized manufacturing and regulatory practices to ensure safety and reproducibility.

This review synthesizes recent research to propose a precision framework for treating androgenetic alopecia and alopecia areata based on genetic insights and pathway biology, highlighting the roles of androgen-receptor signaling, immune dysregulation, and emerging therapies like regenerative medicine and AI-assisted diagnostics.

This review highlights that exosome-based therapies show promise for hair regeneration by modulating signaling pathways and enhancing hair follicle regeneration; however, further clinical research is needed due to variability in methods and limited clinical studies.

Rutin may help regrow hair by stabilizing β-catenin and blocking GSK3β.

This study suggests that minoxidil may promote hair growth in androgenetic alopecia by increasing intracellular calcium, which enhances stem cell differentiation, offering insights for new drug development.

This study found that in AGA, the risk allele at locus 2q35 alters WNT10A expression through EBF1, suggesting a potential androgen-dependent regulatory mechanism.

This study reported that adding the topical product CG210 to oral finasteride 1mg significantly increased hair diameter more than finasteride alone in male androgenetic alopecia patients already stabilized on finasteride treatment.

This study reported that the topical treatment HDMHG0401-10 significantly improved hair density in men with androgenetic alopecia compared to placebo, although subjective hair growth ratings were not significantly different.

HDMHG0401-10 improves hair loss in men with androgenetic alopecia and has no major side effects.

This study found that DEFB1 polymorphisms, specifically the rs1800972 CG and GG genotypes, may predict susceptibility to and severity of alopecia areata.

In this study, a novel compound named AH-001 demonstrated effective androgen receptor protein degradation, reducing hair loss progression in a mouse model of androgenetic alopecia, with minimal systemic exposure and side effects, suggesting potential for safer treatment.